Enfusion Statistics
Total Valuation
Enfusion has a market cap or net worth of $1.39 billion. The enterprise value is $1.35 billion.
| Market Cap | 1.39B |
| Enterprise Value | 1.35B |
Important Dates
The next estimated earnings date is Thursday, May 8, 2025, before market open.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Enfusion has 129.00 million shares outstanding. The number of shares has increased by 0.09% in one year.
| Current Share Class | 94.80M |
| Shares Outstanding | 129.00M |
| Shares Change (YoY) | +0.09% |
| Shares Change (QoQ) | +0.45% |
| Owned by Insiders (%) | 2.14% |
| Owned by Institutions (%) | 51.50% |
| Float | 46.32M |
Valuation Ratios
The trailing PE ratio is 491.69 and the forward PE ratio is 36.77.
| PE Ratio | 491.69 |
| Forward PE | 36.77 |
| PS Ratio | 4.91 |
| Forward PS | 5.76 |
| PB Ratio | 13.91 |
| P/TBV Ratio | 18.96 |
| P/FCF Ratio | 44.71 |
| P/OCF Ratio | 40.02 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 106.53, with an EV/FCF ratio of 43.61.
| EV / Earnings | 479.59 |
| EV / Sales | 6.72 |
| EV / EBITDA | 106.53 |
| EV / EBIT | 219.96 |
| EV / FCF | 43.61 |
Financial Position
The company has a current ratio of 3.42, with a Debt / Equity ratio of 0.20.
| Current Ratio | 3.42 |
| Quick Ratio | 3.16 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | 0.95 |
| Debt / FCF | 0.65 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 4.42% and return on invested capital (ROIC) is 3.62%.
| Return on Equity (ROE) | 4.42% |
| Return on Assets (ROA) | 3.05% |
| Return on Invested Capital (ROIC) | 3.62% |
| Return on Capital Employed (ROCE) | 5.31% |
| Revenue Per Employee | $176,388 |
| Profits Per Employee | $2,470 |
| Employee Count | 1,143 |
| Asset Turnover | 1.60 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Enfusion has paid $3.47 million in taxes.
| Income Tax | 3.47M |
| Effective Tax Rate | 47.02% |
Stock Price Statistics
The stock price has increased by +16.40% in the last 52 weeks. The beta is 0.93, so Enfusion's price volatility has been similar to the market average.
| Beta (5Y) | 0.93 |
| 52-Week Price Change | +16.40% |
| 50-Day Moving Average | 11.10 |
| 200-Day Moving Average | 9.83 |
| Relative Strength Index (RSI) | 42.68 |
| Average Volume (20 Days) | 1,424,225 |
Short Selling Information
The latest short interest is 1.30 million, so 1.01% of the outstanding shares have been sold short.
| Short Interest | 1.30M |
| Short Previous Month | 948,035 |
| Short % of Shares Out | 1.01% |
| Short % of Float | 2.81% |
| Short Ratio (days to cover) | 1.46 |
Income Statement
In the last 12 months, Enfusion had revenue of $201.61 million and earned $2.82 million in profits. Earnings per share was $0.03.
| Revenue | 201.61M |
| Gross Profit | 136.74M |
| Operating Income | 6.16M |
| Pretax Income | 5.67M |
| Net Income | 2.82M |
| EBITDA | 12.71M |
| EBIT | 6.16M |
| Earnings Per Share (EPS) | $0.03 |
Balance Sheet
The company has $54.48 million in cash and $20.31 million in debt, giving a net cash position of $34.17 million or $0.26 per share.
| Cash & Cash Equivalents | 54.48M |
| Total Debt | 20.31M |
| Net Cash | 34.17M |
| Net Cash Per Share | $0.26 |
| Equity (Book Value) | 99.54M |
| Book Value Per Share | 0.77 |
| Working Capital | 66.19M |
Cash Flow
In the last 12 months, operating cash flow was $34.68 million and capital expenditures -$3.64 million, giving a free cash flow of $31.05 million.
| Operating Cash Flow | 34.68M |
| Capital Expenditures | -3.64M |
| Free Cash Flow | 31.05M |
| FCF Per Share | $0.24 |
Margins
Gross margin is 67.82%, with operating and profit margins of 3.05% and 1.40%.
| Gross Margin | 67.82% |
| Operating Margin | 3.05% |
| Pretax Margin | 3.66% |
| Profit Margin | 1.40% |
| EBITDA Margin | 6.30% |
| EBIT Margin | 3.05% |
| FCF Margin | 15.40% |
Dividends & Yields
Enfusion does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.09% |
| Shareholder Yield | -0.09% |
| Earnings Yield | 0.20% |
| FCF Yield | 2.24% |
Analyst Forecast
The average price target for Enfusion is $12.25, which is 13.53% higher than the current price. The consensus rating is "Buy".
| Price Target | $12.25 |
| Price Target Difference | 13.53% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Enfusion has an Altman Z-Score of 11.84 and a Piotroski F-Score of 6.
| Altman Z-Score | 11.84 |
| Piotroski F-Score | 6 |